It is reasonable to propose that there may also exist under-appreciated genomic functions for other type II nuclear receptors (e.g., VDR, PPARs, FXR, LXRs, CAR) [84–86] that exert genomic functions in the absence of exogenous ligand and are potential targets in cancer. This evidence concerns the gene PRKAR1A and cancer.